Cancer therapies can affect the whole cardiovascular system, but these cardiotoxic effects are generally reported as changes in left ventricular (LV) ejection fraction. The most common cardiovascular adverse effects are LV dysfunction and heart failure (HF). Other adverse effects include hypertension, acute coronary syndromes, thromboembolic events, rhythm disturbances, and valvular and/or pericardial disease. Hence, prediction, early recognition, and timely management of cardiovascular complications in patients with cancer are gaining importance. This need gave birth to the concept of interdisciplinary cardiology-oncology (cardio-oncology) care delivered through teams of cardiologists, oncologists, and hematologists.Read More.
Promising results for the UM171 molecule in blood stem cell transplants for patients with acute blood cancers.Read More.
Fox Chase Cancer Center researchers have determined that RNA-based next generation sequencing picks up gene fusions in sarcoma tumours that traditional gene testing may not.Read More.
Endometrial carcinoma is a predominant health problem for women worldwide. However, there is a lack of data on genetic mutation frequencies in endometrial cancer patients of different ethnicities and tumor grades. The objective of this study is to provide data regarding mutation frequencies in endometrial cancer patients of different ethnic groups and tumor grades by analyzing large-scale cancer genomic datasets of a database.Read More.
Researchers from Nazarbayev University are studying the application of nanomaterials in thermal ablation therapy. The use of nanomaterials could pose an attractive solution to the issue of side-effects and harmful by-products associated with existing methods, such as the damage of non-cancerous surrounding cells when targeting tumours.Read More.
CAR T-cell (chimeric antigen receptor T-cell) therapy is a recent, exciting advancement as a form of immunotherapy, offering a new, […]Read More.
Researchers have revealed the important role of epigenetic regulation-mediated metabolic reprogramming in lung cancer’s capacity to resist molecular targeted therapy.Read More.
Researchers have shown the key role that a protein called Ran plays in the mobility of ovarian cancer cells. They demonstrated these cells cannot migrate from cancerous sites without the help of Ran.Read More.